Group 1: Event Details - Chongqing Zhifei Biological Products Co., Ltd. will participate in the 2022 Investor Online Collective Reception Day on December 23, 2022 [1] - The event will take place from 15:00 to 17:00, and the login address for the platform is http://rs.p5w.net [1] Group 2: Purpose and Goals - The event aims to enhance corporate governance and improve the quality of listed companies in the Chongqing area [1] - It is organized under the guidance of the Chongqing Securities Regulatory Bureau and in collaboration with the Chongqing Listed Companies Association, Shanghai Stock Exchange Information Network Co., Ltd., and Shenzhen Qianjing Network Co., Ltd. [1] Group 3: Participation and Communication - Senior management of the company will engage in online communication regarding governance, development strategy, and operational status [1] - The company expresses gratitude to investors for their support and encourages active participation [1]

Group 1: Industry Impact and Regulations - The Shandong vaccine incident has a long-term positive impact on the vaccine industry, leading to market consolidation towards compliant companies [3] - The company adheres strictly to GMP and GSP standards, ensuring no business dealings with unqualified entities [3] - Future regulations on vaccine management are expected to become stricter, affecting procurement, cold chain, and distribution processes [4] Group 2: HPV Vaccine Development - The HPV vaccine has shown good application globally, with ongoing technical reviews and administrative approvals [4] - The company has a contract with MSD for the HPV vaccine, which includes a 3-year sales period and a potential 2-year extension upon task completion [4] - The company is currently the sole provider of the AC-Hib combination vaccine, with no immediate competition expected for at least 3 years [4] Group 3: Safety and Efficacy of Domestic Vaccines - Domestic vaccines have demonstrated safety, with only 9 adverse reactions reported from over 100 million doses of measles vaccine in 2010 [5] - The quality of domestic vaccines is approaching or exceeding EU standards, with some indicators even surpassing foreign products [5] - The vaccine industry is expected to undergo a transformation, with a reduction in the number of manufacturers as the market consolidates [4] Group 4: Market Dynamics and Future Strategies - The company anticipates that the vaccine market will not be dominated by a large number of producers, but will gradually concentrate [4] - The recent vaccine incident has prompted the health authorities to strengthen circulation and vaccination management, which may lead to centralized procurement [6] - The company is focusing on early-stage investments in biopharmaceuticals, particularly in oncology, cardiovascular, and metabolic areas [6]